Tensys Medical T-Line ICU Experience Published in British Journal of
Anesthesia.
Full press release below.
SOURCE: Tensys Medical, Inc.
2013 ISICEM
SAN DIEGO--(BUSINESS WIRE)--Tensys
Medical, Inc., a leader in the development and commercialization of
continuous, non-invasive hemodynamic patient monitoring systems, announced that
a scientific paper evaluating the use of the company’s T-line technology has
been published in the British Journal of Anesthesia (03/13/13—advance online
publication). In this study, the investigators compared blood pressure
measurements in 34 medical ICU patients using the TL-200pro non-invasive method
versus invasive femoral artery catheterization. The authors reported that the
TL-200pro system is able to provide mean arterial pressure (MAP) values with
high accuracy and precision when compared to invasively assessed MAP values.
According to Dr. Bernd Saugel, lead author of the paper, “The emerging role of
non-invasive technologies in the monitoring of critically ill patients is
clear, and the TL-200pro is a promising candidate for both patients and physicians
when compared to traditional, invasive approaches.”
“The impact of non-invasive monitoring in the ICU will be even more
pronounced as we will soon add the ability to monitor cardiac output and
additional hemodynamic parameters using our recently 510(k) cleared, next
generation TL-300 platform.”
The TL-200Pro is a member of the T-Line family which has successfully
been used by over 50,000 patients since commercial launch. The technology
accurately and continuously captures a patient’s beat-to-beat waveform and
blood pressure in a completely non-invasive fashion, providing physicians with
a stream of real-time hemodynamic data that is not possible using traditional
non-invasive blood pressure (cuff) devices. Avoiding the blind-time associated
with a deflated or inaccurate cuff can enhance hemodynamic monitoring, which
has been definitively linked to improved clinical outcomes. Today, the T-line
family is used in a number of clinical environments including the operating
room, intensive care unit (ICU), and electrophysiology lab.
“This paper highlights the versatility of the T-line technology. Beyond
the system’s traditional position in the operating room marketplace, the
authors have demonstrated the increasing role the device can play in the
monitoring of very complex medical ICU patients,” commented Dr. Oliver Goedje,
Tensys’ Medical Director. “The impact of non-invasive monitoring in the ICU
will be even more pronounced as we will soon add the ability to monitor cardiac
output and additional hemodynamic parameters using our recently 510(k) cleared,
next generation TL-300 platform.”
Tensys management will be providing additional details regarding this
data and launch of its next generation products as the company exhibits at the
upcoming 2013 International Symposium on Intensive Care and Emergency Medicine
(03/19/13—03/22/13, Brussels, Belgium). For additional details, please visit www.tensysmedical.com
and/or contact Dr. Eric Daniels, Vice President, Marketing & Sales, Tensys
Medical (edaniels@tensysmedical.com)
About Tensys
Tensys Medical, Inc. is a leader in the development and
commercialization of continuous, non-invasive, hemodynamic monitoring systems.
Without a single needle stick, the company's FDA approved and CE-Marked T-line
technology is used today in hospital operating rooms, ICUs and
electrophysiology labs to provide a patient's real-time pulse pressure waveform
and blood pressure. With the future addition of advanced hemodynamic
parameters, Tensys is positioned to continue its leadership in the growing,
non-invasive, hemodynamic marketplace.
Cautionary Statement Regarding Forward-Looking Statements
This press release may include “forward-looking statements” intended to
qualify for the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. These forward-looking statements
generally can be identified by phrases such as “will,” “near future,”
“positioned,” “provide,” or other words or phrases of similar import that are
intended to identify forward-looking statements. Similarly, statements herein
that describe Tensys Medical's business strategy, outlook, objectives, plans,
intentions, or goals also are forward-looking statements. All such
forward-looking statements are subject to certain risks and uncertainties that
could cause actual results to differ materially from those in forward-looking
statements, including: the clinical and commercial potential and success of the
company’s TL-300 product and T-Line product line; general economic and business
conditions; and other risks and important factors that could cause actual
results to differ materially from the forward-looking statements. The
forward-looking statements included in this press release are made only as of
the date of this announcement, and Tensys Medical undertakes no obligation to
update the forward-looking statements to reflect subsequent events or
circumstances after the date on which they were made.
Contacts
Tensys Medical, Inc.
Eric J. Daniels, MD, MBA
Vice President, Marketing
& Sales
TEL: 858-552-1941
FAX: 858-552-1944
edaniels@tensysmedical.com
No comments:
Post a Comment